Role of maternal serum interleukin 17 in preeclampsia: diagnosis and prognosis
Authors El Shahaway AA, Abd Elhady RR, Abdelrhman AA, Yahia S
Received 26 February 2019
Accepted for publication 17 May 2019
Published 11 July 2019 Volume 2019:12 Pages 175—180
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Ning Quan
Alia A El Shahaway,1 Rasha R Abd Elhady,2 Amr Ahmed Abdelrhman,2 Shymaa Yahia1
1Department of Medical Microbiology and Immunology, Faculty of Medicine, Zagazig University, Zagazig, Egypt; 2Department of Obstetrics and Gynecology, Faculty of Medicine, Zagazig University, Zagazig, Egypt
Background: Immunological factors play a unique role in the setting of preeclampsia; there is a rising debate about the performance of interleukin 17 (IL-17) as inflammatory mediator in its pathogenesis. The purpose of this paper was to evaluate the significance of IL-17 in the diagnosis and prognosis of preeclampsia and estimate a cutoff value for better prediction.
Methods: A prospective case control study, 40 patient were enrolled in the study, two groups were designed: a normotensive (control) group (n=20) and preeclampsia group (n=20). Both groups were compared regarding serum IL-17 level to clarify its significance, then ROC curve analysis was done to establish the best cutoff level to predict preeclampsia, with further assessment of its relation to blood pressure to determine its prognostic value.
Results: We noted a statistically significant difference in serum IL-17 (pg/mL) level between the preeclampsia and control group (P<0.05). The best cutoff value of serum IL-17 in preeclampsia was (8.2 pg/mL) with a sensitivity of 100%, specificity 80% and accuracy 89%. There was also significant variation in its concentrations before and after control of blood pressure and a significant positive correlation with systolic blood pressure level (r=0.9).
Conclusion: IL-17 is a significant inflammatory biomarker in preeclampsia with useful prognostic power to predict severity of disease.
Keywords: IL-17, preeclampsia, inflammatory biomarker, hypertension, proteinuria
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]